Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics
Alaina M. Jaster, Javier González‐Maeso
Molecular Psychiatry (2023) Vol. 28, Iss. 9, pp. 3595-3612
Open Access | Times Cited: 22

Showing 22 citing articles:

Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics?
Kenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience (2024)
Open Access | Times Cited: 29
Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways
Jitendra Kumar Sinha, Anchal Trisal, Shampa Ghosh, et al.
Ageing Research Reviews (2024) Vol. 96, pp. 102211-102211
Closed Access | Times Cited: 13
Neural Mechanisms of Resting-State Networks and the Amygdala Underlying the Cognitive and Emotional Effects of Psilocybin
Devon Stoliker, Leonardo Novelli, Franz X. Vollenweider, et al.
Biological Psychiatry (2024) Vol. 96, Iss. 1, pp. 57-66
Open Access | Times Cited: 12
1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents – A Review
Richard A. Glennon, Małgorzata Dukat
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 6, pp. 1722-1745
Open Access | Times Cited: 10
Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis
Marije E. Otto, Katelijne V. van der Heijden, Jan W. Schoones, et al.
Clinical Pharmacokinetics (2025)
Open Access | Times Cited: 1
Psychedelics in the Treatment of Substance Use Disorders and Addictive Behaviors: A Scoping Review
Jérémie Richard, Albert Garcia‐Romeu
Current Addiction Reports (2025) Vol. 12, Iss. 1
Closed Access | Times Cited: 1
A role for the serotonin 2A receptor in the expansion and functioning of human transmodal cortex
Andrea I. Luppi, Manesh Girn, Fernando Rosas, et al.
Brain (2023) Vol. 147, Iss. 1, pp. 56-80
Open Access | Times Cited: 14
Psychedelic-assisted therapy among sexual and gender minority communities
Brady D. Hanshaw, Mark Fusunyan, Chase T. M. Anderson, et al.
Nature Mental Health (2024) Vol. 2, Iss. 6, pp. 636-644
Closed Access | Times Cited: 4
Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review
I. Erkizia-Santamaría, Igor Horrillo, J. Javier Meana, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111249-111249
Closed Access
Catalyst for change: Psilocybin’s antidepressant mechanisms—A systematic review
Joshua Liebnau, Felix Betzler, André Kerber
Journal of Psychopharmacology (2025)
Open Access
Psychedelics for Moral Bioenhancement in Healthy Individuals—A Violation of the Non-Maleficence Principle?
Bor Luen Tang
Psychoactives (2025) Vol. 4, Iss. 1, pp. 5-5
Open Access
IUPHAR Article: Psilocybin induces long-lasting effects via 5-HT2A receptors in mouse models of chronic pain
Eda Köşeli, Belle Buzzi, Torin Honaker, et al.
Pharmacological Research (2025) Vol. 215, pp. 107699-107699
Open Access
Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies
Fahd François Hilal, Jérôme Jeanblanc, Chloé Deschamps, et al.
Journal of Neural Transmission (2024) Vol. 131, Iss. 5, pp. 525-561
Closed Access | Times Cited: 3
‘Mind-Revealing’ Psychedelic States: Psychological Processes in Subjective Experiences That Drive Positive Change
Rúna F. E. Walther, Hein T. van Schie
Psychoactives (2024) Vol. 3, Iss. 3, pp. 411-436
Open Access | Times Cited: 3
Biological Sex Modulates the Efficacy of 2,5-dimethoxy-4-iodoamphetamine (DOI) to Mitigate Fentanyl Demand
Alice J McQueney, Erik J. Garcia
Drug and Alcohol Dependence (2024) Vol. 263, pp. 112426-112426
Closed Access | Times Cited: 1
Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents
Isabel Werle, Leandro J. Bertoglio
Neuroscience & Biobehavioral Reviews (2024), pp. 105899-105899
Closed Access | Times Cited: 1
The selective 5-HT2Areceptor agonist LPH-5 induces persistent and robust antidepressant-like effects in rodents
Anders A. Jensen, Cláudia R. Cecchi, Meghan Hibicke, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Corolaires en neuro-imagerie des effets des psychédéliques classiques : une revue systématique de la littérature
Doriane Dost, Amine Benyamina, Laurent Karila
L Encéphale (2024)
Closed Access
Psilocybin Therapy for Depression: A Review of Current Molecular Knowledge
Marcha Verheijen
Deleted Journal (2024) Vol. 1, Iss. 1
Open Access
Translation-independent association of mRNAs encoding protomers of the 5-HT2A-mGlu2 receptor complex in living cells
Somdatta Saha, Javier González‐Maeso
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Chemical Reactivity Parameters to Analyze Psychedelics: How Do We Explain the Potency of the Drugs?
Ana Martı́nez, A Molina Caballero, Rodrigo Ramírez, et al.
ACS Omega (2024)
Open Access
Psychedelic Therapy: Beyond Brain, Embracing Culture
Inês Hipólito, Sofia Tzima
(2023)
Open Access
Page 1

Scroll to top